Pancreatic cancer
RAS(ON) inhibitors, pan-KRAS and the long wait for a second-line standard.
Each dot is one target. Higher means stronger genetic evidence in people (inherited variants or tumour mutations, whichever is stronger). Further right means more evidence from drugs already in trials or approved.
Scores run from 0 to 1 and are Open Targets' summary of how much evidence exists, not the chance a drug will work. The dividing lines sit at 0.5. Hover a dot for its numbers, click it for the target's page. Source: Open Targets Platform, fetched live.
The 37 targets in the top-left of the chart, strongest genetic evidence first. Click one for its drugs, tractability and other cancers.
All 50 targets, by type of evidence
Ranked by overall score for pancreatic adenocarcinoma on the Open Targets Platform. Darker cells mean stronger evidence of that type.
Peds RMTLmarks the 8 of these targets on the FDA's Pediatric Relevant Molecular Target List: a drug against one of them can be required to be studied in children under the RACE for Children Act.
| Target | Overall | Germline genetics | Somatic | Literature | Clinical |
|---|---|---|---|---|---|
| KRAS KRas proto-oncogene, GTPase | 0.71 | – | 0.91 | ||
| SMAD4 SMAD family member 4 | 0.69 | – | 0.90 | ||
| TP53Peds RMTL tumor protein p53 | 0.69 | – | 0.90 | ||
| CDKN2A cyclin dependent kinase inhibitor 2A | 0.69 | – | 0.89 | ||
| ARID1A AT-rich interaction domain 1A | 0.65 | – | 0.85 | ||
| RNF43 ring finger protein 43 | 0.64 | – | 0.83 | ||
| GNAS GNAS complex locus | 0.61 | – | 0.79 | ||
| TGFBR2 transforming growth factor beta receptor 2 | 0.61 | – | 0.80 | ||
| KMT2C lysine methyltransferase 2C | 0.60 | – | 0.78 | ||
| RBM10 RNA binding motif protein 10 | 0.58 | – | 0.76 | ||
| KMT2D lysine methyltransferase 2D | 0.54 | – | 0.70 | ||
| MAP2K4 mitogen-activated protein kinase kinase 4 | 0.53 | – | 0.70 | ||
| ACVR2A activin A receptor type 2A | 0.53 | – | 0.70 | ||
| POLE DNA polymerase epsilon, catalytic subunit | 0.50 | – | 0.53 | ||
| POLD1 DNA polymerase delta 1, catalytic subunit | 0.49 | – | 0.46 | ||
| PTPRT protein tyrosine phosphatase receptor type T | 0.48 | – | 0.63 | ||
| LRP1B LDL receptor related protein 1B | 0.48 | – | 0.63 | ||
| TOP1 DNA topoisomerase I | 0.48 | – | 0.38 | ||
| CUX1 cut like homeobox 1 | 0.48 | – | 0.62 | ||
| ACVR1B activin A receptor type 1B | 0.47 | – | 0.62 | ||
| EGFRPeds RMTL epidermal growth factor receptor | 0.47 | – | 0.57 | ||
| CDK6Peds RMTL cyclin dependent kinase 6 | 0.47 | – | 0.72 | ||
| KDM6A lysine demethylase 6A | 0.46 | – | 0.60 | ||
| ERBB4 erb-b2 receptor tyrosine kinase 4 | 0.46 | – | 0.72 | ||
| QKI QKI, KH domain containing RNA binding | 0.46 | – | 0.72 | ||
| ZFHX3 zinc finger homeobox 3 | 0.46 | – | 0.76 | ||
| MAP3K13 mitogen-activated protein kinase kinase kinase 13 | 0.46 | – | 0.76 | ||
| MECOM MDS1 and EVI1 complex locus | 0.46 | – | 0.72 | ||
| BRCA2 BRCA2 DNA repair associated | 0.45 | – | 0.58 | ||
| ATMPeds RMTL ATM serine/threonine kinase | 0.45 | – | 0.57 | ||
| AFF3 ALF transcription elongation factor 3 | 0.44 | – | 0.72 | ||
| ACVR1Peds RMTL activin A receptor type 1 | 0.44 | – | 0.61 | ||
| SND1 staphylococcal nuclease and tudor domain containing 1 | 0.44 | – | 0.72 | ||
| GRIN2A glutamate ionotropic receptor NMDA type subunit 2A | 0.44 | – | 0.72 | ||
| CACNA1D calcium voltage-gated channel subunit alpha1 D | 0.44 | – | 0.72 | ||
| HIP1 huntingtin interacting protein 1 | 0.44 | – | 0.72 | ||
| MLLT10 MLLT10 histone lysine methyltransferase DOT1L cofactor | 0.44 | – | 0.72 | ||
| TUBA1C tubulin alpha 1c | 0.44 | – | – | ||
| AR androgen receptor | 0.44 | – | 0.68 | ||
| CDH11 cadherin 11 | 0.44 | – | 0.68 | ||
| CD274Peds RMTL CD274 molecule | 0.43 | – | 0.46 | ||
| RRM1 ribonucleotide reductase catalytic subunit M1 | 0.43 | – | – | ||
| RRM2 ribonucleotide reductase regulatory subunit M2 | 0.43 | – | – | ||
| JAK1Peds RMTL Janus kinase 1 | 0.43 | – | 0.57 | ||
| TYMSPeds RMTL thymidylate synthetase | 0.43 | – | – | ||
| PRIM2 DNA primase subunit 2 | 0.43 | – | – | ||
| NTRK3 neurotrophic receptor tyrosine kinase 3 | 0.43 | – | 0.68 | ||
| TUBB1 tubulin beta 1 class VI | 0.43 | – | – | ||
| NRG1 neuregulin 1 | 0.43 | – | 0.68 | ||
| KDR kinase insert domain receptor | 0.43 | – | 0.46 |
12 biomarkers in Pancreatic cancer have validated or clinical evidence in CIViC
Accepted evidence from CIViC, the open (CC0) expert-curated knowledgebase, searched by the disease name “Pancreatic Cancer”. Level A is validated (for example in guidelines or an approval), level B comes from clinical trials or studies. 31 accepted items exist; the first 31 were read. This is the published evidence, not treatment advice.
- BRCA1 Mutation level B
- BRCA2 Mutation level B
- ERBB2 Overexpression level B
- RRM1 Underexpression level B
- ATM Underexpression level B
- CDKN2A Loss OR CDKN2A Mutation level B
- CDKN2A Mutation level B
- ERBB2 Amplification level B
- KRAS Exon 2 Mutation level B
- KRAS G12D level B
- KRAS G12R level B
- SMAD4 LOSS level B